BL Pharmtech Statistics
Total Valuation
BL Pharmtech has a market cap or net worth of KRW 24.49 billion. The enterprise value is 27.06 billion.
Market Cap | 24.49B |
Enterprise Value | 27.06B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BL Pharmtech has 26.68 million shares outstanding. The number of shares has decreased by -0.52% in one year.
Current Share Class | 26.68M |
Shares Outstanding | 26.68M |
Shares Change (YoY) | -0.52% |
Shares Change (QoQ) | -0.62% |
Owned by Insiders (%) | 27.53% |
Owned by Institutions (%) | n/a |
Float | 19.34M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.94 |
PB Ratio | 1.06 |
P/TBV Ratio | 1.07 |
P/FCF Ratio | 19.40 |
P/OCF Ratio | 18.41 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -4.93 |
EV / Sales | 3.25 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 21.42 |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.27.
Current Ratio | 0.83 |
Quick Ratio | 0.45 |
Debt / Equity | 0.27 |
Debt / EBITDA | n/a |
Debt / FCF | 4.88 |
Interest Coverage | -4.36 |
Financial Efficiency
Return on equity (ROE) is -20.19% and return on invested capital (ROIC) is -7.66%.
Return on Equity (ROE) | -20.19% |
Return on Assets (ROA) | -6.29% |
Return on Invested Capital (ROIC) | -7.66% |
Return on Capital Employed (ROCE) | -14.53% |
Revenue Per Employee | 694.46M |
Profits Per Employee | -457.20M |
Employee Count | 12 |
Asset Turnover | 0.21 |
Inventory Turnover | 2.37 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.29% in the last 52 weeks. The beta is 0.55, so BL Pharmtech's price volatility has been lower than the market average.
Beta (5Y) | 0.55 |
52-Week Price Change | -50.29% |
50-Day Moving Average | 1,014.76 |
200-Day Moving Average | 1,156.10 |
Relative Strength Index (RSI) | 43.81 |
Average Volume (20 Days) | 536,222 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BL Pharmtech had revenue of KRW 8.33 billion and -5.49 billion in losses. Loss per share was -205.87.
Revenue | 8.33B |
Gross Profit | 5.50B |
Operating Income | -3.97B |
Pretax Income | -5.55B |
Net Income | -5.49B |
EBITDA | -3.12B |
EBIT | -3.97B |
Loss Per Share | -205.87 |
Balance Sheet
The company has 3.62 billion in cash and 6.16 billion in debt, giving a net cash position of -2.54 billion or -95.27 per share.
Cash & Cash Equivalents | 3.62B |
Total Debt | 6.16B |
Net Cash | -2.54B |
Net Cash Per Share | -95.27 |
Equity (Book Value) | 23.08B |
Book Value Per Share | 864.29 |
Working Capital | -1.71B |
Cash Flow
In the last 12 months, operating cash flow was 1.33 billion and capital expenditures -67.78 million, giving a free cash flow of 1.26 billion.
Operating Cash Flow | 1.33B |
Capital Expenditures | -67.78M |
Free Cash Flow | 1.26B |
FCF Per Share | 47.33 |
Margins
Gross margin is 66.02%, with operating and profit margins of -47.62% and -65.84%.
Gross Margin | 66.02% |
Operating Margin | -47.62% |
Pretax Margin | -66.63% |
Profit Margin | -65.84% |
EBITDA Margin | -37.41% |
EBIT Margin | -47.62% |
FCF Margin | 15.15% |
Dividends & Yields
BL Pharmtech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.52% |
Shareholder Yield | n/a |
Earnings Yield | -22.40% |
FCF Yield | 5.16% |
Stock Splits
The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.
Last Split Date | Feb 26, 2025 |
Split Type | Forward |
Split Ratio | 3 |
Scores
BL Pharmtech has an Altman Z-Score of -1.27. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.27 |
Piotroski F-Score | n/a |